Solid Tumor Completed Phase 1 Trials for Alisertib (DB05220)
Also known as: Cancer - Solid Tumors / Solid Tumour / Solid Tumours / Tumor, Solid / Solid Neoplasms / Solid tumour/cancer / Solid Cancers / Cancer: Solid Tumors / Neoplasms, Solid Tumor / Cancer, Solid Tumor / Tumors, Solid / Solid Tumor Cancer / Solid Tumors or Cancers / Solid Tumors / Solid Neoplasm / Cancer (Solid Tumors) / Solid Tumor Neoplasms / Solid Tumor Cancers / Solid Cancer / Neoplasm / Neoplasm (morphologic abnormality) / Neoplasms of unspecified behavior / Neoplasms NOS / Neoplasms NOS (disorder) / [M]Neoplasms NOS (morphologic abnormality) / Neoplasm (NOS) / Tumor / Neoplasm NOS / Tumour / Tumour NOS / Neoplasms / Tumour, NOS / Tumor NOS / Neoplasm, NOS / Tumor, NOS / Neoplasms benign, malignant and unspecified (incl cysts and polyps)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0030180 (Solid Tumor) | Completed | 1 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT02214147 | Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function | Treatment | |
| NCT01898078 | Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas | Treatment | |
| NCT01512758 | A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas | Treatment | |
| NCT01844583 | Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib | Treatment | |
| NCT02719691 | Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer | Treatment | |
| NCT02444884 | MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors | Treatment |